Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ian Haydock

Tokyo, Japan
Ian is head of pharma news content for the Asia-Pacific area and has been covering the region for more than 20 years as an editor for Scrip and more recently as managing editor of PharmAsia News. He has a long background in Asia, having grown up in Hong Kong, and a particular interest in regional regulatory harmonization and trade initiatives and the development of the Japanese pharma sector. Ian lives in Tokyo with his wife and two sons.
Set Alert for Articles By Ian Haydock

Latest From Ian Haydock

Japan Approvals Include World Firsts For Romosozumab, Spinal Injury Cell Therapy

The latest group of new product approvals in Japan includes the first marketing clearances worldwide for fracture-reducing osteoporosis antibody romosozumab, a stem cell-based therapy for spinal cord injury, two new Daiichi drugs, and Pfizer's lung cancer therapy dacomitinib. 

Japan Approvals

NEC Moves Beyond IT Tools As It Pursues AI-Driven Drug Discovery Initiative

In an exclusive interview, Japanese tech giant NEC tells Scrip it is aiming for much more than the provision of IT tools in its AI-assisted Drug Discovery Initiative, hoping also to progress assets deriving from cutting-edge technology research. 

Artificial Intelligence Business Strategies

Asia Deal Watch: Boost For Esperion's Cholesterol Candidate As Daiichi Brought On Board

Daiichi Sankyo pays $150m upfront to commercialize Esperion's cholesterol drug and combination in Europe, while Gilead enters major deal worth up to $785m with Korea's Yuhan to bolster its NASH portfolio. Samsung taps 3SBio to build its biosimilars business in China. 
Deals Asia Pacific

Takeda's Weber: ‘Everything Relies On Our Ability To Deliver Innovative Medicines’

With the formal completion of its huge acquisition of Shire now just a day away, some eight months after it was first announced, Takeda CEO presses home what he sees as the key priorities and benefits of the combined operation - but the real work to realize these is just beginning.

M & A Japan

New Takeda R&D Collabs Aim To Boost IO Pipeline

In moves aimed at boosting its presence in the immuno-oncology field, Takeda unveils a series of new research collaborations it believes will lead to pipeline gains in this critical field over the next few years.

Cancer Research and Development Strategies

Japan 2018 Review: Takeda/Shire Dominates But Pharma Life Goes On

2018 in Japan wasn't all about Takeda and Shire - though it mostly was. Amid a generally quiet year for M&A otherwise, companies concentrated on honing their specialty focus, dealing with major patent expiries, and fretting about big changes to the country's pricing system.

Japan Commercial
See All